Management of Atrial Fibrillation in the Elderly

Anticoagulation Therapy

• The American College of Cardiology recommends oral anticoagulation with a direct oral anticoagulant (DOAC) for patients with atrial fibrillation and a high risk of stroke, such as those aged 75 years, with a target international normalized ratio (INR) not applicable for DOACs 1, 2, 5
• The American Heart Association suggests that age alone is never a contraindication to anticoagulation in high-risk patients, with a stroke risk of 2-5% annually without anticoagulation 5, 4
• The European Society of Cardiology recommends direct oral anticoagulants over warfarin due to lower intracranial hemorrhage risk and elimination of INR monitoring, with apixaban 5 mg twice daily as the standard dose 3, 4

Rate Control Strategy

• The American College of Cardiology recommends rate control with chronic anticoagulation as the initial strategy for most patients with atrial fibrillation, with a goal resting heart rate of <100 bpm 3, 4, 6
• Beta-blockers, such as metoprolol, are first-line for rate control in patients without structural heart disease or heart failure, with non-dihydropyridine calcium channel blockers as alternative agents 3, 4
• The American Heart Association advises against using digoxin as the sole agent for rate control in active patients, as it fails to control heart rate during exercise 2, 3

Essential Baseline Evaluation and Monitoring

• The American College of Cardiology recommends obtaining a 12-lead ECG, renal function tests, thyroid function tests, electrolytes, complete blood count, hepatic function tests, and a transthoracic echocardiogram before initiating treatment 3, 4
• Renal function monitoring is recommended at least annually when using DOACs, with more frequent monitoring if clinically indicated 3, 4
• The European Society of Cardiology advises against discontinuing anticoagulation after cardioversion or if sinus rhythm is restored, as stroke risk persists based on underlying risk factors 3, 4